Previous 10 | Next 10 |
Data was presented during the 16 th International Congress of the Society for Melanoma Research Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that Derek Maetzold, president and chief executive officer, will present at the following upcoming investor conferences:...
Image source: The Motley Fool. Castle Biosciences, Inc. (NASDAQ: CSTL) Q3 2019 Earnings Call Nov 11, 2019 , 4:30 p.m. ET Operator Continue reading
Castle Biosciences, Inc. (CSTL) Q3 2019 Earnings Conference Call November 11, 2019 04:30 PM ET Company Participants Frank Stokes - Chief Financial Officer Derek Maetzold - Founder, President & Chief Executive Officer Conference Call Participants Catherine Schulte - Baird ...
Castle Biosciences (NASDAQ: CSTL ): Q3 GAAP EPS of $0.05 beats by $0.35 . More news on: Castle Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Q3 2019 DecisionDx-Melanoma test report volume increased 32% compared to Q3 2018 Q3 2019 recognized revenues increased to $14.8 million, up from $3.7 million in Q3 2018 Q3 2019 gross margin increased to 88%, up from 64% in Q3 2018 December 2019 salesforce expansion Presented cli...
Data presented at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of re...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of a development update and validation data for its cutaneous squamous cell carcinoma (SCC) prognostic ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of data supporting clinical use of the DecisionDx ® -Melanoma test to inform decisions of whether ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that it will release its financial results for the third quarter ended September 30, 2019, after the close of market on ...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NASDAQ Market:
Castle Biosciences Inc. Website:
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Canaccord Genuity 44 th Annual Growth Conference on Tuesday, Aug. 13, 2024, at ...
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...